GlassScriptPhysician profile
Stephanie L Cotell
NPI 1922093459
$204,854.85
in general payments reported to CMS, 2019-2025
52 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $20K · 2021: $14K · 2022: $26K · 2023: $52K · 2024: $27K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Food and Beverage: $22K · Travel and Lodging: $4,298 · Consulting Fee: $1,900 · Education: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,175.00 |
| Food and Beverage | $22,218.08 |
| Travel and Lodging | $4,298.09 |
| Consulting Fee | $1,900.00 |
| Education | $439.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $130,450.09 | 2019-2025 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $31,763.04 | 2019-2025 | |
| Incyte Corporation | $5,322.84 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $4,861.11 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Journey Medical Corporation | $4,236.70 | 2019-2025 | |
| Janssen Biotech, INC. | $3,188.67 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,898.86 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,828.17 | 2019-2025 | Siliq, Arazlo, Cabtreo |
| Genzyme Corporation | $1,801.89 | 2019-2025 | |
| Ucb, INC. | $1,634.68 | 2019-2025 | Bimzelx, Cimzia |
| Almirall LLC | $1,521.41 | 2019-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $1,430.25 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,308.74 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $1,293.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,270.04 | 2019-2025 | Dupixent, Libtayo |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,222.22 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $1,176.91 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,027.88 | 2019-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,004.40 | 2021-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $991.60 | 2019-2025 | Winlevi, Absorica Ld |
| Vyne Pharmaceuticals INC. | $884.06 | 2020-2021 | |
| Biofrontera INC. | $745.80 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $567.06 | 2020-2024 | Neo-Synalar, Neuac |
| Promius Pharma LLC | $518.88 | 2019 | |
| Epi Health, LLC | $338.79 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $333.93 | 2020-2025 | Tremfya |
| Celgene Corporation | $305.10 | 2019 | |
| Dermira, INC. | $255.26 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $245.00 | 2020-2021 | |
| Organon LLC | $206.59 | 2025 | Vtama, Nexplanon |
| Eli Lilly and Company | $175.00 | 2021 | |
| Krystal Biotech INC | $127.91 | 2023-2024 | Vyjuvek |
| Strata Skin Sciences, INC. | $107.95 | 2023 | Xtrac |
| Organogenesis INC. | $100.01 | 2020-2025 | Simplimax |
| Allergan, INC. | $76.64 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $74.56 | 2019 | |
| Sebela Pharmaceuticals INC. | $74.13 | 2021-2022 | |
| Encore Dermatology INC. | $67.15 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $65.27 | 2024 | Nuzyra |
| Integra Lifesciences Corporation | $62.34 | 2019 | |
| Merz North America, INC. | $62.03 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $47.47 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.08 | 2024 | Spevigo |
| Pierre Fabre Pharmaceuticals, INC. | $24.95 | 2025 | Hemangeol |
| Kerecis Limited | $20.51 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sandoz INC. | $19.36 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.66 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.88 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.43 | 2023 | Veregen |
| Kaleo, INC. | $15.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Stemline Therapeutics INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Cotell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.